graph EGM comparisons
atezolizumab alonetitlenivolumab alonetitledurvalumab alonetitlepembrolizumab alonetitlenivolumab plus SoCtitleatezolizumab plus carboplatin plus nab-paclitaxeltitleatezolizumab plus bevacizumab plus carboplatin plus paclitaxeltitlecemiplimabtitleatezolizumab plus carboplatin plus paclitaxeltitleavelumab alonetitlepembrolizumab plus SoCtitlepembrolizumab (10mg/kg)titlepembrolizumab (2mg/kg)titleTislelizumabtitleatezolizumab plus pemetrexed and platintitlesintillimab plus SoCtitledurvalumab plus osimertinibtitlepembrolizumab and pemetrexed plus platintitlenab-paclitaxeltitleplacebo plus SoCtitleosimertinibtitlecarboplatin plus nab-paclitaxeltitleStandard of Care (SoC)titlepemetrexed plus platintitlebevacizumab plus carboplatin and paclitaxeltitleplacebotitledocetaxeltitlePACIFIC, 2017 NCT02125461 laNSCLC - M - all population 476/237CheckMate 816, 2022 NCT02998528 locally advanced NSCLC - (neo)adjuvant (NA) 179/179EMPOWER lung1 (all population), 2021 NCT03088540 mNSCLC - L1 - all population 356/354MYSTIC (D ; all population), 2020 NCT02453282 mNSCLC - L1 - all population 374/372ORIENT-11, 2020 NCT03607539 mNSCLC - L1 - all population 266/131CheckMate 227 (NC vs C ; PDL1<1%), 2018 NCT02477826 mNSCLC - L1 - PDL1 negative 177/186IMpower-110 (TC3 or IC3), 2020 NCT02409342 mNSCLC - L1 - PDL1 positive 107/98IMpower-110 (TC2/3 or IC2/3), 2020 NCT02409342 mNSCLC - L1 - PDL1 positive 166/162IMpower-110 (TC1/2/3 or IC1/2/3), 2020 NCT02409342 mNSCLC - L1 - PDL1 positive 277/277EMPOWER lung1 (PDL1>50%), 2021 NCT03088540 mNSCLC - L1 - PDL1 positive 283/280MYSTIC (D ; PDL1>25%), 2020 NCT02453282 mNSCLC - L1 - PDL1 positive 163/162CheckMate 026 (PDL1>1%), 2016 NCT02041533 mNSCLC - L1 - PDL1 positive 271/270CheckMate 026 (PDL1>5%), 2016 NCT02041533 mNSCLC - L1 - PDL1 positive 211/212KEYNOTE-042 (PDL1>20%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 413/405KEYNOTE-042 (PDL1>50%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 299/300KEYNOTE-042 (PDL1>1%), 2019 NCT02220894 mNSCLC - L1 - PDL1 positive 637/637KEYNOTE-024 (PDL1>50%), 2016 NCT02142738 mNSCLC - L1 - PDL1 positive 154/151OAK (all population), 2016 NCT02008227 mNSCLC - L2 - all population 613/612POPLAR, 2016 NCT01903993 mNSCLC - L2 - all population 144/143JAVELIN Lung 200 (all population), 2018 NCT02395172 mNSCLC - L2 - all population 396/396CheckMate 078, 2019 NCT02613507 mNSCLC - L2 - all population 338/166RATIONALE 303, 0 NCT03358875 mNSCLC - L2 - all population -9/-9CAURAL (EXPLORATORY), 2019 NCT02454933 mNSCLC - L2 - EGFR mutant 14/15OAK (PDL1 TC 1/2/3), 2016 NCT02008227 mNSCLC - L2 - PDL1 positive 347/337JAVELIN Lung 200 (PDL1 >1%), 2018 NCT02395172 mNSCLC - L2 - PDL1 positive 264/265ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 NCT02352948 mNSCLC - L2 - PDL1 positive 62/64KEYNOTE-010 (P:10 mg/kg), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 346/343KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 151/152KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 139/152KEYNOTE-010 (P: 2mg/kg), 2016 NCT01905657 mNSCLC - L2 - PDL1 positive 344/343IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 NCT02366143 non squamous - mNSCLC - L1 - all population 400/400IMpower-130 (all population), 2019 NCT02367781 non squamous - mNSCLC - L1 - all population 483/240IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 NCT02366143 non squamous - mNSCLC - L1 - all population 402/400IMpower-150 (ABCP vs BPC WT), 2018 NCT02366143 non squamous - mNSCLC - L1 - Wild Type (WT) 356/336IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 NCT02366143 non squamous - mNSCLC - L1 - Wild Type (WT) 155/129IMpower-130 (WT), 2019 NCT02367781 non squamous - mNSCLC - L1 - Wild Type (WT) 451/228IMpower-132 (WT), 0 NCT02657434 non squamous - mNSCLC - L1 - Wild Type (WT) 292/286KEYNOTE-021, 2016 NCT02039674 non squamous - mNSCLC - L1 - Wild Type (WT) 60/63KEYNOTE-189, 2018 NCT02578680 non squamous - mNSCLC - L1 - Wild Type (WT) 410/206CheckMate 057, 2015 NCT01673867 non squamous - mNSCLC - L2 - all population 292/290CheckMate 816, 2022 NCT02998528 NSCLC neoadjuvant setting 179/179IMpower-131 (ACnP), 2020 NCT02367794 squamous - mNSCLC - L1 - all population 343/340IMpower-131 (ACP) EXPLORATORY, 2020 NCT02367794 squamous - mNSCLC - L1 - all population 338/340KEYNOTE-407, 2018 NCT02775435 squamous - mNSCLC - L1 - all population 278/281CheckMate 017, 2015 NCT01642004 squamous - mNSCLC - L2 - all population 135/137

Pathology:  laNSCLC - M - all population;   locally advanced NSCLC - (neo)adjuvant (NA);   mNSCLC - L1 - all population;   mNSCLC - L1 - PDL1 negative;   mNSCLC - L1 - PDL1 positive;   mNSCLC - L2 - all population;   mNSCLC - L2 - EGFR mutant;   mNSCLC - L2 - PDL1 positive;   non squamous - mNSCLC - L1 - all population;   non squamous - mNSCLC - L1 - Wild Type (WT);   non squamous - mNSCLC - L2 - all population;   NSCLC neoadjuvant setting;   squamous - mNSCLC - L1 - all population;   squamous - mNSCLC - L2 - all population; 

laNSCLC - M - all populationlocally advanced NSCLC - (neo)adjuvant (NA)mNSCLC - L1 - all populationmNSCLC - L1 - PDL1 negativemNSCLC - L1 - PDL1 positivemNSCLC - L2 - all populationmNSCLC - L2 - EGFR mutantmNSCLC - L2 - PDL1 positivenon squamous - mNSCLC - L1 - all populationnon squamous - mNSCLC - L1 - Wild Type (WT)non squamous - mNSCLC - L2 - all populationNSCLC neoadjuvant settingsquamous - mNSCLC - L1 - all populationsquamous - mNSCLC - L2 - all population
PACIFIC, 2017CheckMate 816, 2022EMPOWER lung1 (all population), 2021MYSTIC (D ; all population), 2020ORIENT-11, 2020CheckMate 227 (NC vs C ; PDL1<1%), 2018IMpower-110 (TC3 or IC3), 2020IMpower-110 (TC2/3 or IC2/3), 2020IMpower-110 (TC1/2/3 or IC1/2/3), 2020EMPOWER lung1 (PDL1>50%), 2021MYSTIC (D ; PDL1>25%), 2020CheckMate 026 (PDL1>1%), 2016CheckMate 026 (PDL1>5%), 2016KEYNOTE-042 (PDL1>20%), 2019KEYNOTE-042 (PDL1>50%), 2019KEYNOTE-042 (PDL1>1%), 2019KEYNOTE-024 (PDL1>50%), 2016OAK (all population), 2016POPLAR, 2016JAVELIN Lung 200 (all population), 2018CheckMate 078, 2019RATIONALE 303, 0CAURAL (EXPLORATORY), 2019OAK (PDL1 TC 1/2/3), 2016JAVELIN Lung 200 (PDL1 >1%), 2018ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020KEYNOTE-010 (P:10 mg/kg), 2016KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016KEYNOTE-010 (P: 2mg/kg ; PDL1>50%), 2016KEYNOTE-010 (P: 2mg/kg), 2016IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018IMpower-130 (all population), 2019IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018IMpower-150 (ABCP vs BPC WT), 2018IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018IMpower-130 (WT), 2019IMpower-132 (WT), 0KEYNOTE-021, 2016KEYNOTE-189, 2018CheckMate 057, 2015CheckMate 816, 2022IMpower-131 (ACnP), 2020IMpower-131 (ACP) EXPLORATORY, 2020KEYNOTE-407, 2018CheckMate 017, 2015
atezolizumab alone6T1T1T1T1T1T1
nivolumab alone5T1T1T1T1T1
durvalumab alone4T1T1T1T1
pembrolizumab alone4T1T1T1T1
nivolumab plus SoC3T1T1T1
atezolizumab plus carboplatin plus nab-paclitaxel3T1T0T1T1
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel3T1T1T1
cemiplimab2T1T1
atezolizumab plus carboplatin plus paclitaxel2T1T1
avelumab alone2T1T1
pembrolizumab plus SoC2T1T1
pembrolizumab (10mg/kg)2T1T1
pembrolizumab (2mg/kg)2T1T1
Tislelizumab1T1
atezolizumab plus pemetrexed and platin1T1
sintillimab plus SoC1T1
durvalumab plus osimertinib1T1
pembrolizumab and pemetrexed plus platin1T1
nab-paclitaxel0T0
placebo plus SoC0T0T0T0T0T0
osimertinib0T0
carboplatin plus nab-paclitaxel0T0T0
Standard of Care (SoC)0T0T0T0T0T0T0T0T0T0T0T0T0T0T0
pemetrexed plus platin0T0T0T0
bevacizumab plus carboplatin and paclitaxel0T0T0T0T0
placebo0T0
docetaxel0T0T0T0T0T0T0T0T0T0T0T0T0T0